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The Whole Quilt, or Just a STICH?*Jeffrey B. Geske, MD, Bernard J. Gersh, MB, CHB, DPHILI n this issue of the Journal, Jolicœur et al. (1)assessed the role of angina in regard to the out-comes of revascularization of ischemic cardio-
myopathy by performing a subgroup analysis of the
STICH (Surgical Treatment for Ischemic Heart Failure)
trial (2). Angina has long played a central role in the
management of patients with coronary artery disease
(CAD) and ischemic cardiomyopathy, with some cur-
rent guidelines citing the presence of angina as a ma-
jor inﬂuence upon the decision to perform coronary
revascularization (3). The authors pose 3 questions:
1. Does angina confer an adverse prognosis in patients
with left ventricular (LV) systolic dysfunction?
2. Does angina predict a survival beneﬁt in patients
undergoing coronary artery bypass grafting (CABG)?
3. Does CABG relieve angina better than medical
therapy alone in patients with LV dysfunction?SEE PAGE 2092Of 1,212 patients with LV ejection fraction #35%
randomized to CABG versus medical therapy, 770 re-
ported the presence of angina. When stratifying
solely on the basis of the presence or absence of
angina, there was no difference in all-cause mortality
in patients randomized to medical therapy alone.
However, in the relatively few (7.5%) patients with
Canadian Cardiovascular Society class III or IV angina,
worse all-cause mortality was noted. Data from the*Editorials published in the Journal of the American College of Cardiology
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reduction in all-cause death and cardiovascular hos-
pitalization in patients undergoing CABG compared
with medical therapy alone (hazard ratio [HR]: 0.74;
95% conﬁdence interval [CI]: 0.64 to 0.85; p < 0.001)
(2); yet, somewhat counterintuitively, in this subset
analysis of patients with and without angina analyzed
by intention to treat, CABG did not reduce all-cause
death in patients with angina. However, when
crossovers were considered, CABG did reduce all-
cause mortality in patients with and without angina.
CABG was more likely to improve symptoms of angina
compared with medical therapy alone, a ﬁnding that
was consistent throughout follow-up.
With these data, the authors conclude that “the
presence or absence of angina should not be used as a
discriminating factor to decide for or against revas-
cularization as an initial treatment strategy, so far as
subsequent prognosis is concerned” (1). This sweep-
ing statement must be put into the context of the trial
population. Beyond potential enrollment biases, trial
subjects were largely male (87.8%), young (w60 years
of age), and recruited outside of North America.
Angina classiﬁcation was not standardized across
sites, and relatively few of the patients studied had
Canadian Cardiovascular Society class III/IV angina.
Furthermore, there are several confounding factors:
patients without angina were more likely to have
diabetes and had more viable myocardium, whereas
long-acting nitrates were utilized more frequently in
patients with angina. Although the authors’ conclu-
sion is appropriate to the trial population, it may not
apply to patients with more severe angina or even to
patients with LV dysfunction as a whole.
Analyses of STICH data have demonstrated that the
severity of CAD burden directly inﬂuences the bene-
ﬁts of CABG (4). Similarly, in the CASS (Coronary
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ated with CABG in patients with LV dysfunction
and 3-vessel disease CAD (5). However, the extent of
CAD does not necessarily translate to the severity (or
even presence) of angina. The degree of luminal ste-
nosis, magnitude of ischemic myocardium, and
resultant angina may be discordant, particularly in
patients known to exhibit atypical angina, such as
women and those with diabetes. However, an anal-
ysis of patients in the CASS registry on the basis of the
predominance of angina versus heart failure symp-
toms revealed that those with angina as the pre-
dominant symptom and an ejection fraction #35%
had better survival following CABG than patients with
mostly heart failure symptoms (6). Does the differ-
ence from the present study relate to interval evolu-
tion of medical therapy, or are we seeing a selection
effect?
The concepts of reversible LV dysfunction following
revascularization and hibernating myocardium are
decades old (7,8). It is worthwhile, however, to clarify
terminology that is often interchanged. Viable
myocardium refers to nonscarred tissue with potential
for recovery and may be normally functioning at rest
(with inducible ischemia) or stunned at rest (in the
presence of resting ischemia). In contrast, hibernating
myocardium is a term applied retrospectively to
denote myocardium that improves following revas-
cularization (9). In considering the complex interplay
of angina and viability, it is worth revisiting the STICH
viability substudy data (10). Whereas patients with
presence of viable myocardium had better outcomes
than those without (HR: 0.64; 95% CI: 0.48 to 0.86;
p ¼ 0.003), CABG did not result in an incremental
survival beneﬁt in patients with viability when
compared with medical therapy alone (HR: 0.86; 95%
CI: 0.64 to 1.16; p ¼ NS). There have been many pro-
posed explanations for this result, including the un-
blinded and nonrandomized nature of viability
testing, the combination of viability techniques (sin-
gle-photon emission computed tomography and
dobutamine echocardiography), dichotomous classi-
ﬁcation of viability (as opposed to continuous assess-
ment), and a relatively small subset with 3-vessel CAD
(36%). Regardless, the results raised many questions
regarding the utility of viability testing within this
patient population.
Further complicating the matter, STICH data sug-
gests that in patients with severe LV dysfunction,
inducible myocardial ischemia does not identify pa-
tients with worse prognosis or greater beneﬁt from
CABG (11). How do we synthesize these data and apply
them to clinical practice? In managing patients with
ischemic cardiomyopathy, can we blind ourselves tothe presence of angina, ischemia, and viability? One
possible explanation for the discrepancy between
ischemia and observed outcomes is the extent of un-
derlying scar burden, which was not considered in this
analysis. Hachamovitch et al. (12) studied a large
cohort of patients undergoing adenosine or exercise-
stress single-photon emission computed tomography
myocardial perfusion scintigraphy and found that in
patients without an extensive scar burden (deﬁned as
scar encompassing >10% of myocardium), signiﬁcant
ischemia was predictive of survival beneﬁts associated
with early revascularization, whereas patients with
extensive scar did not achieve such beneﬁts. These
data imply that ischemia is a predictor of outcomes;
however, its inﬂuence may be superseded by the
presence of a signiﬁcantly scarred underlying sub-
strate. Scar burden and extensive remodeling may
similarly lead to the observed disconnect between
measures of viability and outcomes.
The STICH trial has provided substantial informa-
tion on the inﬂuence (or lack thereof) of viability,
ischemia, and now the presence or absence of angina.
Although the main ﬁnding, that CABG provides a
modest beneﬁt in a sick group of patients with LV
dysfunction, is intuitive, other STICH trial results
have been unexpected and raised many further
questions. Established concepts of viability, ische-
mia, and angina have been placed into question. Do
the results mean that these factors should be dis-
counted as inﬂuences on decision making for revas-
cularization? Certainly not. Rather, these data
suggest that as ischemic heart disease progresses,
there comes a point in the natural history when the
severity of LV dysfunction, extent of scarring, and
adverse ventricular remodeling may overwhelm
viability and ischemia as the major determinants of
prognosis. In such patients, the incremental beneﬁts
of revascularization over optimal medical therapy
alone may be minimal.
We agree that viability testing should not be a
routine part of the evaluation in patients with LV
dysfunction, but there are subsets in whom it may be
helpful. As with many trials, providing an answer to
one question generates a host of others. How appli-
cable are the STICH results outside of the population
studied? How much scar negates the inﬂuence of
viability? In the presence of severe LV dysfunction, at
what point are the beneﬁts of revascularization over
medical therapy lost? Because STICH trial data have
shown a trend toward survival beneﬁt of revascular-
ization, irrespective of the presence or absence of
viability (9) (more so in patients with 3-vessel CAD
[3]), we must consider the pluripotent effects of
revascularization beyond improvement in regional
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2103contractile function of hibernating myocardium. The
effect of revascularization on prevention of ventric-
ular arrhythmias, improved diastolic hemodynamics,
attenuation of maladaptive remodeling, or a host of
other factors may prove paramount in certain patient
populations.
In conclusion, integration of these results into
clinical practice necessitates careful attention to the
patient population that was studied. When treating
patients with lesser degrees of LV dysfunction, CAD
that is not completely revascularizable, or patients athigh surgical risk, additional information, such as the
extent of viability, extent of ischemia, scar burden,
and the effect of angina symptoms on quality of life,
may still be helpful in the therapeutic decision-
making process.
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